NASDAQ:ODT - Odonate Therapeutics Stock Price, Price Target & More

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.

3 equities research analysts have issued 1-year target prices for Odonate Therapeutics' shares. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next year. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Ratings for Odonate Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Odonate Therapeutics include Clovis Oncology (CLVS), Endo International (ENDP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC) and Insmed (INSM).

(ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Since the end of Odonate Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Headlines about ODT stock have been trending somewhat positive on Sunday, according to Accern. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Odonate Therapeutics earned a news sentiment score of 0.19 on Accern's scale. They also gave news headlines about the company an impact score of 45.16 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $23.57.

Odonate Therapeutics has a market capitalization of $633.75 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]